Skip to content
vigabatrin.org

The Vigabatrin REMS program

On this page

Form matters for each dose. The ready-to-use liquid needs no mixing; powder is mixed before every dose. In one small study funded by the liquid’s maker, doses made from the liquid were more accurate. Compare the forms

Short answer: the Vigabatrin REMS is an FDA-required safety program built around the risk of permanent vision loss. Vigabatrin is available only through it: the prescriber must be certified, the patient must be enrolled, and the medicine can only be dispensed by a certified pharmacy.1 Contact details from the labels are www.vigabatrinREMS.com and 1-866-244-8175.1,2

REMS stands for Risk Evaluation and Mitigation Strategy. The requirements on this page are summarized from the FDA labels for vigabatrin, not from the program's own website, which may have more detail on forms and steps.2

Why vigabatrin has a REMS

Vigabatrin can cause permanent narrowing of side vision in both eyes, and it can also reduce sharpness of vision. The risk rises with dose and with time on the medicine, and no dose is known to be free of risk.1 Based on adult studies, 30% or more of patients can be affected.3 The labels describe vigabatrin as a treatment for people in whom the possible benefits outweigh this risk, and the REMS adds controls on who can prescribe and dispense it, alongside a schedule of vision checks.1

The REMS applies to every form. The labels for the ready-to-use liquid, the Sabril powder sachets and tablets, and generic powder such as Vigadrone all carry the same boxed warning and the same REMS requirement.1,2,3,4

The three requirements

The labels list three parts:1

WhoWhat the label requires
PrescriberMust be certified in the Vigabatrin REMS
PatientMust be enrolled in the Vigabatrin REMS
PharmacyMust be certified; only certified pharmacies can dispense vigabatrin

In practice, this means a prescription for vigabatrin cannot simply be filled at any pharmacy. The medicine comes from a pharmacy that is part of the program. Ask the prescriber's office which pharmacy they use and who to call about refills.

The vision-check schedule

The labels set a schedule of vision assessments:1

  • no later than 4 weeks after starting vigabatrin
  • at least every 3 months while on it
  • about 3 to 6 months after stopping

The REMS was designed around this baseline exam plus ongoing monitoring.5 For babies, standard field tests are not possible, so eye specialists may use other tests such as an electroretinogram, which measures how the retina responds to light.5

Keep a note of each eye appointment. If a check is missed, tell the prescriber.

What the REMS means for families

Researchers interviewed patients and caregivers about REMS programs like this one. The group included 10 people taking vigabatrin and 4 vigabatrin caregivers. People said the programs reassured them, but they also described real burdens, such as having to travel to reach a certified prescriber or pharmacy, and educational materials that were hard to understand.6

A companion study interviewed 31 physicians, 6 of whom prescribed vigabatrin. They understood the REMS but felt it changed their practice only a little, and they raised concerns about paperwork and administrative load.7

Practical steps that may help:

  • Ask the prescriber's team to explain the enrollment forms in plain words. You can ask for a copy of what you sign.
  • Ask for the certified pharmacy's phone number and the usual delivery time, so refills do not run late.
  • Put every vision check in your calendar as soon as it is booked.
  • If you change prescriber, pharmacy or insurance, check that the new one is part of the program before your supply runs low. Only certified prescribers and pharmacies can take part.1
  • Bring questions about the vision risk to each visit. The vigabatrin FAQ covers many common ones.

Starting, switching and stopping

Starting. For infantile spasms, the label advises stopping vigabatrin if it has not clearly helped within 2 to 4 weeks. For refractory complex partial seizures, the limit is 3 months.3 Because the vision risk rises with time on the medicine, this limits exposure when it is not working.1

Switching forms. Moving between powder and the ready-to-use liquid changes the volume of each dose, because the liquid is twice as concentrated. The label warns prescribers, pharmacists and caregivers to confirm the new volume.1

Stopping. The label says not to stop vigabatrin suddenly; it should be withdrawn gradually to avoid more seizures.1,3 A final vision check is due about 3 to 6 months after the last dose.1

Common questions

What is the Vigabatrin REMS?

It is a safety program required by the FDA because of vigabatrin's risk of permanent vision loss. Vigabatrin is available only through it. Prescribers and pharmacies must be certified, and each patient must be enrolled.

How do I contact the Vigabatrin REMS?

The FDA labels list the website www.vigabatrinREMS.com and the phone number 1-866-244-8175.

Does the ready-to-use liquid need the REMS too?

Yes. The Vigafyde, Sabril and generic (for example Vigadrone) labels all carry the same boxed vision-loss warning and say the medicine is available only through the Vigabatrin REMS.

How often does my child need vision checks under the REMS?

The label asks for a vision assessment no later than 4 weeks after starting, at least every 3 months during treatment, and about 3 to 6 months after stopping.

References

  1. 1.VIGAFYDE (vigabatrin) oral solution prescribing information, revised 11/2025. Source
  2. 2.Vigabatrin REMS: www.vigabatrinREMS.com (as cited in both labels). Requirements as summarized under label-vigafyde-2025 §5.2. (The REMS website itself was not fetched; requirements are cited from the FDA labels.) Source
  3. 3.SABRIL (vigabatrin) tablets prescribing information, revised 10/2021. Source
  4. 4.VIGADRONE (vigabatrin) for oral solution, revised 12/2025, Upsher-Smith. Source
  5. 5.Sergott RC, Westall CA. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin. Acta Neurol Scand Suppl. 2011;(192):48-56. PMID 22061180 · DOI 10.1111/j.1600-0404.2011.01600.x PubMedDOI
  6. 6.Sarpatwari A, Brown BL, McGraw SA, et al. Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use. JAMA Netw Open. 2022;5(1):e2144386. PMID 35050352 · DOI 10.1001/jamanetworkopen.2021.44386 PubMedDOI
  7. 7.Sarpatwari A, Brown BL, McGraw SA, et al. Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use. PLoS One. 2023;18(7):e0288008. PMID 37410756 · DOI 10.1371/journal.pone.0288008 PubMedDOI

All sources used on this site, with summaries